Dr. Theresa Heah.

PALM BEACH GARDENS, Fla.—Curative Biotechnology Inc. (OTC: CUBT), a development-stage biomedical company focused on novel treatments for degenerative eye diseases, announced the nomination of Dr. Theresa Heah to its board of directors. Dr. Heah is expected to join its board of directors immediately as an independent director. In addition to other board duties, Dr. Heah will serve on the newly created Clinical Development Committee of the board. An accomplished executive, Dr. Heah brings more than two decades of drug development and commercial experience, with an emphasis on ophthalmology and gene therapy, and recently served as the chief executive officer and a member of the board of directors at Intergalactic Therapeutics, an Apple Tree Partners company.

She serves as an advisor to several venture capital firms and ophthalmology companies and has recently become the chief executive officer of Paratus Sciences and a member of its board of directors.

Previously, she served as president and chief medical officer at Kriya Therapeutics, where she launched the ophthalmology division, Kriya Ophthalmology, and was responsible for building its AAV gene therapy portfolio strategy. Prior to joining Kriya, Dr. Heah served as executive vice president of operations and chief medical officer at AsclepiX Therapeutics, where she led the company’s advancement of its pipeline products into the clinic.

She also previously served as chief medical officer at Applied Genetic Technologies Corporation, working to develop gene therapies in ophthalmology and rare diseases, and has led multiple successful global ophthalmic innovations, regulatory submissions and commercialization of products, including Ozurdex, Eylea, Rhopressa and Rocklatan.

“We welcome Dr. Heah with great enthusiasm,” said Paul Michaels, executive chairman of Curative and CEO of Curative’s wholly owned Japanese subsidiary Curative Biotech Japan K.K. “Dr. Heah’s invaluable insights and guidance will significantly bolster Curative as we venture into clinical development of our metformin-based eye drops to treat degenerative eye diseases and beyond.”

“I share the enthusiasm and look forward to collaborating with the esteemed leadership and scientists at Curative Biotech in developing and advancing innovative products aimed at preserving vision,” Dr. Heah said.